Arousal Training for Social Anxiety Disorder

NCT ID: NCT02493010

Last Updated: 2017-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to examine the safety, usability and preliminary efficacy of a novel arousal-based biofeedback system in alleviating social anxiety. The investigators hypothesize that after 4 weeks of hour-long interventions, participants will show reductions pre- and post-intervention in their Liebowitz Social Anxiety Scale scores.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators plan to conduct a waitlist control trial.

Intervention consists of a combination of computerized cognitive behavioral therapy and arousal-based Virtual Reality Exposure Therapy. During the latter component, the physiological variables of participants, such as pulse rate and EEG, will be continuously monitored and presented as feedback to them. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Anxiety

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Virtual Reality Exposure Therapy Computerized Cognitive Behavioral Therapy Public Speaking Social Phobia Biofeedback

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.

Group Type EXPERIMENTAL

Arousal-based biofeedback system

Intervention Type DEVICE

Waitlist Control

Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arousal-based biofeedback system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Literate in English
* Computer literate
* Able to travel independently
* Agreeable to being video-recorded when going through study protocol
* Liebowitz Social Anxiety Scale score of 31 or more
* Public Speaking Anxiety Scale score of 60 or more
* Alcohol Use Disorders Identification Test (AUDIT) of 8 and below

Exclusion Criteria

* Has gross visual or hearing impairments
* Has irregular heart rhythm
* On any psychoactive medication
* Involved in any other long-term research study
* Current or previous history of neuropsychiatric disorders (other than depression, which will be assessed by BDI-II)
* Suicide ideation
* Concurrent psychotherapy for any disorder
* Non-responding to a previous psychotherapy
Minimum Eligible Age

21 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Agency for Science, Technology and Research

OTHER

Sponsor Role collaborator

Singapore General Hospital

OTHER

Sponsor Role collaborator

Duke-NUS Graduate Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lee Tih Shih

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tih-Shih Lee, MD PHD

Role: PRINCIPAL_INVESTIGATOR

Duke-NUS Graduate Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duke-NUS Graduate Medical School

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

References

Explore related publications, articles, or registry entries linked to this study.

Lin XB, Lee TS, Cheung YB, Ling J, Poon SH, Lim L, Zhang HH, Chin ZY, Wang CC, Krishnan R, Guan C. Exposure Therapy With Personalized Real-Time Arousal Detection and Feedback to Alleviate Social Anxiety Symptoms in an Analogue Adult Sample: Pilot Proof-of-Concept Randomized Controlled Trial. JMIR Ment Health. 2019 Jun 14;6(6):e13869. doi: 10.2196/13869.

Reference Type DERIVED
PMID: 31199347 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B-14-098

Identifier Type: -

Identifier Source: org_study_id